Deniz Işık

26PUBLICATIONS
81CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersInnate immunityMolecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Sep 26, 2026
FOLFOX Plus Bevacizumab Rechallenge Versus Regorafenib as Third-Line Treatment in Metastatic Colorectal Cancer: The Role of the Oxaliplatin-Free Interval.

|Jun 26, 2026
Prognostic Significance of Preoperative PET-CT SUVmax in Resected Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.

|Mar 14, 2026
Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk-Stratified Analysis.

Sila Oksuz, Oguzcan Kinikoglu, Ugur Ozkerim

|Feb 27, 2026
Association Between Body Mass Index and Clinical Outcomes of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer: A Real-World Cohort Study.

Seval Orman, Miray Aydoğan, Nisanur Sarıyar Busery

|Jan 28, 2026
Adjuvant Chemotherapy and Chemoradiotherapy in Gastric Cancer: Prognostic Determinants and Real-World Survival Outcomes.

Sedat Yildirim, Hatice Odabas, Seval Ay Ersoy

|Jan 28, 2026
Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study.

Ugur Ozkerim, Oguzcan Kinikoglu, Sila Oksuz

Pageof 5

Frequent Collaborators

24 joint publications

Hatice Odabas

23 joint publications

Oğuzcan Kınıkoğlu

22 joint publications

Nedim Turan

18 joint publications

Sedat Yıldırım